GeoVax Holders Approve Reverse Split and 11.4M Warrant-Exercise Shares
GOVX is trading near its 52-week low of $0.19 (8.3% above the low) on light trading volume (0.2× avg).
Summary
GeoVax stockholders approved both the reverse stock split (1-for-10 to 1-for-25, ratio set by the Board) and the issuance of up to 11,395,256 shares on exercise of the August 2026 inducement warrants. The votes clear the path to a Nasdaq bid-price cure, but the delisting appeal outcome is not disclosed here.
Key Events · Corporate Governance and Compliance · GOVX
-
Reverse Split Approved by Holders
Stockholders approved an amendment to the Certificate of Incorporation permitting a reverse split of not less than 1-for-10 and not greater than 1-for-25, with the exact ratio left to the Board. The vote was 3,484,374 for, 828,802 against and 12,837 abstaining.
-
Warrant-Exercise Share Issuance Cleared
The August 2026 Warrant Exercise Proposal passed 1,492,403 to 458,659 (44,131 abstaining, 2,330,820 broker non-votes), approving issuance of up to 11,395,256 shares on exercise of warrants issued to an institutional investor in the August 25, 2026 inducement.
-
No New Dilution From This Vote
The 11,395,256 shares were already committed under the August 2026 warrant inducement; this vote satisfies Nasdaq's shareholder-approval requirement rather than creating a new issuance. The split itself does not change ownership percentages.
-
Delisting Appeal Outcome Still Open
The Nasdaq staff delisting determination and the October 13, 2026 appeal hearing remain the binding constraint; this filing does not state the appeal result or a deadline for the Board to set the split ratio.
Analysis · GOVX · Life Sciences
Both proposals before the October 27 special meeting passed, clearing the two items that mattered most for a company facing a Nasdaq delisting determination. The reverse split (anywhere from 1-for-10 to 1-for-25, with the Board picking the exact ratio) is the company's route back to the $1.00 minimum bid; the warrant-exercise approval lets the 11,395,256 shares underlying the August 2026 inducement warrants be issued without running afoul of Nasdaq's 20% rule. Neither vote creates new dilution beyond what was already disclosed — the warrants were issued in the August 25, 2026 inducement, and the split changes the share count without changing ownership percentages. Still unresolved: the delisting appeal heard October 13, 2026, whose outcome is not stated in this filing, and the Board's still-undetermined split ratio and timing.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOVX was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.19 to $15.17. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.